Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Abstract Text:

BACKGROUND: This study examined whether different ondansetron dosing schedules plus dexamethasone influenced antiemetic efficacy during multiple cycles of cisplatin-based chemotherapy (CT). Antiemetic activities between previous CT and subsequent cycles were compared. METHODS: The cross-over study involved 424 patients. Arm A, three doses of 8 mg ondansetron given intravenously (IV) at 4-hourly intervals plus dexamethasone 20 mg IV at the start of CT, followed by dexamethasone 5 mg IV every 12 hours. Arm B, as arm A but the three doses of 8 mg ondansetron were given at 24-hourly intervals. For those with complete protection from emesis in both arms, a single dose of 8 mg ondansetron (arm C) was tried during the following CT. Once complete protection of emesis could not be maintained, arm A regimens were administered in the subsequent cycles of CT. RESULTS: There were 384, 377 and 147 patients in arm A, arm B and arm C, respectively. Complete control of acute and delayed nausea/vomiting obtained in arm A were 91.4%/94.8% and 59.6%/70.1%, and in arm B were 90.4%/92.3% and 61.3% 72.7%. There was no significant difference in antiemetic efficacy between both arms. Decreased incidence of and delayed onset of nausea on day 2 were observed in arm B (p = 0.002). The emetic severity during previous CT correlated significantly with those of the subsequent CT. The complete control of nausea/vomiting was maintained in 81.6%/72.1% of arm C patients during the following 3rd-6th cycles of CT. CONCLUSION: No difference in antiemetic efficacy was shown when a triple 8 mg dose of ondansetron was given at 4-hourly intervals or at 24-hourly intervals. However, the latter improved nausea on day 2. A single 8 mg dose of ondansetron can maintain antiemetic efficacy in the majority of complete responders in arm A and arm B.

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Chang Gung medical journal

VOLUME: 31

Page Numbers: 167-74

Journal Abbreviation:

ISSN:

DAY: 23

MONTH: 06

YEAR: 2008

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101088034

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.

AFFILIATION:

Country: China (Republic : 1949- )

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Chang Gung Med J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy Related Publications

• A novel mechanism of transcriptional repression of p27kip1 through Notch/HRT2 signaling in vascular smooth muscle cells.
• Assessment of readiness to prevent type 2 diabetes in a population of rural women with a history of gestational diabetes.
• Bioavailability effect of methylprednisolone by polymeric micelles.
• Comparative Studies on Expression of alpha-Smooth Muscle Actin in Hepatic Stellate Cells in Chronic Hepatitis B and C.
• Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer.
• Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?
• EPR, UV-Vis, IR, and X-ray demonstration of the anionic dimeric dinitrosyl iron complex [(NO)(2)Fe(micro-S(t)Bu)(2)Fe(NO)(2)](-): relevance to the products of nitrosylation of cytosolic and mitochondrial aconitases, and high-potential iron proteins.
• Exploring learners' self-efficacy, autonomy and motivation toward e-learning.
• Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters.
• Fatal hemoptysis after suction through endotracheal tube in a patient with pneumoconiosis--a case report.
• Gene Gun Bombardment with DNA-Coated Gold Particles Is a Potential Alternative to Hydrodynamics-Based Transfection for Delivering Genes into Superficial Hepatocytes.
• Hairy-Related Transcription Factors Inhibit Notch-Induced Smooth Muscle {alpha}-Actin Expression by Interfering With Notch Intracellular Domain/CBF-1 Complex Interaction With the CBF-1-Binding Site.
• Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
• Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists.
• Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
• Mononuclear Ni(II)-thiolate complexes with pendant thiol and dinuclear Ni(III/II)-thiolate complexes with Ni...Ni interaction regulated by the oxidation levels of nickels and the coordinated ligands.
• New Members of a Class of Dinitrosyliron Complexes (DNICs): Interconversion and Spectroscopic Discrimination of the Anionic {Fe(NO)2}(9) [(NO)2Fe(C3H3N2)2](-) and [(NO)2Fe(C3H3N2)(SR)](-) (C3H3N2 = Deprotonated Imidazole; R = (t)Bu, Et, Ph).
• Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.
• Numerical renormalization-group approach to a sandpile.
• Oxygen binding to sulfur in nitrosylated iron--thiolate complexes: relevance to the Fe-containing nitrile hydratases.
• Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.
• Role of RppA in the regulation of polymyxin b susceptibility, swarming, and virulence factor expression in Proteus mirabilis.
• Single-longitudinal-mode fiber laser with a passive multiple-ring cavity and its application for video transmission.
• Soil dioxins levels at agriculture sites and natural preserve areas of Taiwan.
• Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
• Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
• Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center.
• Transfusion-related acute lung injury--a report of two and the possible role of steroid.
• Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma.
• Widespread delta-like-1 expression in normal adult mouse tissue and injured endothelium is reflected by expression of the Dll1LacZ locus.